HLA-DRB1 alleles and genotypes in patients with relapsing-remitting multiple sclerosis from western Mexico: a pilot study

被引:0
|
作者
Alfonso Cruz-Ramos, Jose [1 ,2 ,3 ]
Gabriel Ortiz, Genaro [1 ,2 ,3 ]
Ignacio Diaz-Barba, Eduardo [1 ,2 ,3 ]
Angel Macias-Islas, Miguel [4 ]
Mireles-Ramirez, Mario [4 ]
机构
[1] IMSS, CIBO, Lab Desarrollo Envejecimiento, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico
[2] IMSS, CIBO, Enfermedades Neurodegenerat, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico
[3] IMSS, CIBO, Div Neurociencias, Guadalajara, Jalisco, Mexico
[4] IMSS, CMNO, Hosp Especialidades, UMAE,Dept Neurol, Guadalajara, Jalisco, Mexico
来源
INVESTIGACION CLINICA | 2017年 / 58卷 / 04期
关键词
HLA-DRB1; relapsing-remitting multiple sclerosis; risk; alleles; genotypes; Mexican mestizo; CLASS-II ALLELES; MESTIZO POPULATION; HLA; RISK; SUSCEPTIBILITY; HAPLOTYPES; RESISTANCE; ADMIXTURE; THERAPY; MARKERS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The HLA-DRB1 alleles are closely related to genetic susceptibility to multiple sclerosis (MS). There is a high prevalence of MS in Caucasian populations, whereas non-Caucasian populations have a low prevalence. In Latin American countries, genomes are made up of a heterogeneous gene pool, which varies between different regions of each country. The objective of this study was to evaluate the association of alleles and genotypes of HLA-DRBI in relapsing-remitting multiple sclerosis (RRMS) in Mexican Mestizos of western Mexico. HLA-DRB1 alleles and genotypes were determined for 59 RRMS patients and 434 healthy subjects. The results show that allele HLA-DRB1*15 (p: 0.013, OR: 2.74) was associated with risk of RRMS, no others alleles were significantly associated. Whereas, a risk tendency was observed for alleles HLA-DRB1*09 (p: 0.062, OR: 6.24), HLA-DRB1*04 (p: 0.086, OR: 1.876) and genotypes HLA-DRf31*15/*13 (p: 0.068, OR: 15.71), HLA-DRBI*15/*04 (p: 0.068, OR: 6.35). Otherwise, the alleles HLA-DRB1*08 (p: 0.062, OR: 0.340) and HLA-DRB1*01(p: 0.062, OR: 0.29) show tendency to a protective effect. Further research is required about risk alleles in larger patient RRMS cohorts in western Mexico. HLA-DRBI risk allelic variation in different regions of Mexico for MS further illustrates the genetic heterogeneity of the Mexican population and the Caucasian influence in shaping the epidemiology of MS in Mexico.
引用
收藏
页码:323 / 333
页数:11
相关论文
共 50 条
  • [31] Cholesterol level correlate with disability score in patients with relapsing-remitting form of multiple sclerosis
    Durfinova, M.
    Prochazkova, E.
    Petrlenicova, D.
    Bystricka, Z.
    Oresanska, K.
    Kuracka, E.
    Liska, B.
    NEUROSCIENCE LETTERS, 2018, 687 : 304 - 307
  • [32] Pausing and fluency in speech of patients with relapsing-remitting multiple sclerosis
    Bona, Judit
    CLINICAL LINGUISTICS & PHONETICS, 2024, 38 (04) : 332 - 344
  • [33] Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis
    Ramagopalan, Sreeram V.
    Sadovnick, A. Dessa
    Ebers, George C.
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (01) : 127 - 128
  • [34] The High Prevalence of the Varicella Zoster Virus in Patients With Relapsing-Remitting Multiple Sclerosis: A Case-Control Study in the North of Iran
    Najafi, Saeideh
    Ghane, Masood
    Yousefzadeh-Chabok, Shahrokh
    Amiri, Mehdi
    JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2016, 9 (03)
  • [35] Facial emotion recognition in patients with relapsing-remitting multiple sclerosis
    Fereydouni, Soodabe
    Hadianfard, Habib
    Ashjazadeh, Nahid
    NEUROLOGY ASIA, 2019, 24 (04) : 327 - 332
  • [36] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [37] Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis
    Nielsen, T. R.
    Rostgaard, K.
    Askling, J.
    Steffensen, R.
    Oturai, A.
    Jersild, C.
    Koch-Henriksen, N.
    Sorensen, P. S.
    Hjalgrim, H.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (04) : 431 - 436
  • [38] Influence of the HLA-DRB1 Genotype on Antibody Development to Interferon Beta in Multiple Sclerosis
    Buck, Dorothea
    Cepok, Sabine
    Hoffmann, Steve
    Grummel, Verena
    Jochim, Angela
    Berthele, Achim
    Hartung, Hans-Peter
    Wassmuth, Ralf
    Hemmer, Bernhard
    ARCHIVES OF NEUROLOGY, 2011, 68 (04) : 480 - 487
  • [39] The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis
    Derfuss, T.
    Sastre-Garriga, J.
    Montalban, X.
    Rodegher, M.
    Wuerfel, J.
    Gaetano, L.
    Tomic, D.
    Azmon, A.
    Wolf, C.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (01)
  • [40] Association of HLA-DRB1*1501 tagging rs3135388 gene polymorphism with multiple sclerosis
    Benesova, Yvonne
    Vasku, Anna
    Stourac, Pavel
    Hladikova, Magdalena
    Fiala, Adam
    Bednarik, Josef
    JOURNAL OF NEUROIMMUNOLOGY, 2013, 255 (1-2) : 92 - 96